QT
CNCE

Quantamental Technologies’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Quantamental Technologies’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,230
Closed -$19K – 1488
2019
Q3 		$19K Buy
3,230
+1,006
+45% +$10.7K 0.01% 1216
2019
Q2 		$27K Buy
+2,224
New +$23.9K 0.01% 1079

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Quantamental Technologies's CNCE Position: Q4 2019 in Review

Quantamental Technologies sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2019, closing a stake of 3,230 shares — an estimated $19K sold.

Quantamental Technologies first reported a position in CNCE in Q2 2019 and held it in 2 quarters. The position peaked at $27K in Q2 2019. 77 funds tracked by Wall St. Rank hold CNCE as of Q4 2019.

  • Quantamental Technologies reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Quantamental Technologies sold 3,230 Concert Pharmaceuticals, Inc. shares in Q4 2019, an estimated $19K.
  • Quantamental Technologies first reported a position in Concert Pharmaceuticals, Inc. in Q2 2019 and held it in 2 quarters.
  • Quantamental Technologies's Concert Pharmaceuticals, Inc. position peaked at $27K in Q2 2019.
  • 77 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.